Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Horizon Therapeutics
Deal Size : $3,050.0 million
Deal Type : Acquisition
Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.
Details : Horizon Therapeutics gets UPLIZNA, first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder.
Product Name : Uplizna
Product Type : Antibody
Upfront Cash : $3,005.0 million
March 15, 2021
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Horizon Therapeutics
Deal Size : $3,050.0 million
Deal Type : Acquisition
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Horizon Therapeutics
Deal Size : $3,050.0 million
Deal Type : Acquisition
Details : Horizon adds UPLIZNA® (inebilizumab-cdon) to its commercial rare disease medicine portfolio. The acquisition Adds deep, mid-stage biologics pipeline focused primarily on autoimmune and severe inflammatory diseases.
Product Name : Uplizna
Product Type : Antibody
Upfront Cash : $3,005.0 million
January 02, 2021
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Horizon Therapeutics
Deal Size : $3,050.0 million
Deal Type : Acquisition
Lead Product(s) : VIB7734
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The interim findings indicated safety and tolerability comparable to placebo control across all cohorts, potent depletion of pDC both in peripheral blood and in inflamed CLE skin lesion biopsies in cohort 2, and dose-dependent reduction in CLASI after tr...
Product Name : VIB7734
Product Type : Antibody
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : VIB7734
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020
Details : First poster will highlights study results in AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Product Name : Uplizna
Product Type : Antibody
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
